A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
收藏DataCite Commons2025-11-14 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001483/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.
提供机构：
Vivli
创建时间：
2018-10-27
